Abstract:A subset of cardiomyocytes acquires a senescence‐associated secretory phenotype (SASP) when subjected to doxorubicin (Dox). SASP cardiomyocytes affect healthy non‐senescent cardiomyocytes, rendering them senescent through delivery of exosomes. Clearance of senescent cardiomyocytes using the Bcl‐2 inhibitor ABT‐199 alleviates senescence of cardiomyocytes and prevents chemotherapy‐related cardiotoxicity. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐related cardiotoxicity and could be a new therapeutic target for Dox‐induced cardiac injury. Doxorubicin (Dox), an anthracycline antibiotic, is widely used in cancer treatment. Although its antitumor efficacy appears significant, its clinical use is greatly restricted by its induction of cardiotoxicity. Cardiac senescence drives the Dox‐induced cardiotoxicity, but whether diminishing these senescent cardiomyocytes could alleviate the cardiotoxicity remains unclear. Here, we assessed whether senescent cardiomyocytes have a senescence‐associated secretory phenotype (SASP) that affects healthy non‐senescent cardiomyocytes, rendering them senescent via the delivery of exosomes. Additionally, we explored whether targeting SASP senescent cardiomyocytes using a Bcl‐2 inhibitor could alleviate cardiotoxicity. Cardiac damage was induced in a mouse model of continuous Dox treatment in vivo, and cardiomyocytes in vitro. Immunofluorescence of the senescence markers of Cdkn2a, Cdkn1a and γ‐H2A.X was used to assess the SASP in the Dox‐treated heart. To explore the molecular mechanisms involved, the Bcl‐2 inhibitor ABT‐199 was employed to eliminate SASP senescent cardiomyocytes. We show that the cardiomyocytes acquire a SASP during Dox treatment. The senescent cardiomyocytes upregulated Bcl‐2, although treatment of mice with ABT‐199 selectively eliminated SASP senescent cardiomyocytes involved in Dox‐induced cardiotoxicity, thus leading to partial alleviation of Dox‐induced cardiotoxicity. Moreover, we concluded that SASP factors secreted by senescent cardiomyocytes induced by Dox renders otherwise healthy cardiomyocytes senescent through exosome delivery. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐dependent cardiotoxicity and indicate that targeting the clearance of SASP senescent cardiomyocytes could be a new therapeutic approach for Dox‐induced cardiac injury.

Sphingosylphosphorylcholine ameliorates doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by reducing excessive mitophagy and mitochondrial dysfunction

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

Saikosaponin D Alleviates DOX-induced Cardiac Injury In Vivo and In Vitro

Breviscapine Remodels Myocardial Glucose and Lipid Metabolism by Regulating Serotonin to Alleviate Doxorubicin-Induced Cardiotoxicity

Calycosin attenuates doxorubicin-induced cardiotoxicity via autophagy regulation in zebrafish models

USP14 modulates cell pyroptosis and ameliorates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing SIRT3

Substance P prevents doxorubicin‐induced cardiomyocyte injury by regulating apoptosis and autophagy: In vitro and in vivo evidence

Spexin inhibits excessive autophagy-induced ferroptosis to alleviate doxorubicin-induced cardiotoxicity by upregulating Beclin 1

Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion

Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy

Capsaicin alleviates doxorubicin-induced acute myocardial injury by regulating iron homeostasis and PI3K-Akt signaling pathway

Gp130-mediated STAT3 Activation by S-propargyl-cysteine, an Endogenous Hydrogen Sulfide Initiator, Prevents Doxorubicin-Induced Cardiotoxicity

Harpagoside Protects Against Doxorubicin-Induced Cardiotoxicity via P53-Parkin-Mediated Mitophagy

Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity

LCZ696 Improves Cardiac Function Via Alleviating Drp1-mediated Mitochondrial Dysfunction in Mice with Doxorubicin-Induced Dilated Cardiomyopathy.

Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling.

Calycosin ameliorates doxorubicin‐induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1–NOD‐like receptor protein 3 pathway

AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice